Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.40 |
| ▸ | MLYCD | O95822 | 5/20 | 0.39 |
| ▸ | MGLL | Q99685 | 2/20 | 0.37 |
| ▸ | CNR1 | P21554 | 2/20 | 0.36 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.35 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.35 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.35 |
| ▸ | RORC | P51449 | 1/20 | 0.35 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.34 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.34 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4430547 | 0.89 | MLYCD (0.41) | MLYCDNR1H3NR1H2RORC | |
| SCHEMBL4422260 | 0.86 | MLYCD (0.38) | MLYCD | |
| SCHEMBL4424260 | 0.84 | PLAU (0.41) | — | |
| SCHEMBL4424179 | 0.83 | MLYCD (0.39) | MLYCDCNR1RORCTRPV1 | |
| SCHEMBL4420347 | 0.80 | MLYCD (0.41) | MLYCDNR1H3NR1H2TRPV1 | |
| SCHEMBL4430579 | 0.79 | TRPV4 (0.47) | CD274 | |
| SCHEMBL4417912 | 0.79 | EGLN1 (0.46) | MLYCDRORC | |
| SCHEMBL4428901 | 0.76 | MLYCD (0.42) | MLYCDNR1H3NR1H2 | |
| SCHEMBL4879317 | 0.76 | EGLN1 (0.43) | MLYCDNR1H3NR1H2 | |
| SCHEMBL4871566 | 0.74 | MLYCD (0.42) | MLYCDNR1H3NR1H2RORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4267920-B2 | — | — | 2009-05-27 | — | — | JP | claimed |
| US-20080070869-A1 | Malonyl-CoA Decarboxylase Inhibitors Useful as Metabolic Modulators | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2008-03-20 | — | — | US | claimed |
| US-7279477-B2 | Malonyl-CoA decarboxylase inhibitors useful as metabolic modulators | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2007-10-09 | — | — | US | claimed |
| JP-2004523542-A | — | — | 2004-08-05 | — | — | JP | claimed |
| US-20040063671-A1 | Malonyl-coa decarboxylase inhibitors useful as metabolic modulators | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2004-04-01 | — | — | US | claimed |
| EP-1377290-A2 | MALONYL-COA DECARBOXYLASE INHIBITORS USEFUL AS METABOLIC MODULATORS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2004-01-07 | — | — | EP | claimed |
| WO-2002064136-A2 | MALONYL-COA DECARBOXYLASE INHIBITORS USEFUL AS METABOLIC MODULATORS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2002-08-22 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063671-A1 | Malonyl-coa decarboxylase inhibitors useful as metabolic modulators | MLYCD, ACACA, ME1 | EGLN2 1831/4885MLYCD 1/4885MGLL 285/4885 |
| US-20080070869-A1 | Malonyl-CoA Decarboxylase Inhibitors Useful as Metabolic Modulators | MLYCD, ME3, ACACA | EGLN2 1756/4885MLYCD 1/4885MGLL 251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.